Alembic Pharma gets final USFDA nod for hypertension drug
- Country:
- India
Alembic Pharmaceuticals (Alembic) on Friday said it has received final nod from US health regulator for Bosentan tablets, used for treatment of pulmonary arterial hypertension. "Alembic Pharmaceuticals Ltd (Alembic) today announced it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosentan tablets, 62.5 mg and 125 mg," the firm said in a BSE filing.
Bosentan tablets is for the treatment of pulmonary arterial hypertension. "ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tracleer Tablets, 62.5 mg and 125 mg, of Actelion Pharmaceuticals Ltd," the filing said.
Bosentan Tablets, 62.5 mg and 125 mg have an estimated market size of USD 68 million for twelve months ending September 2019, according to IQVIA. Alembic has a cumulative total of 114 ANDA approvals from USFDA.
The shares of Alembic Pharmaceuticals were trading at Rs 597.85 apiece on the BSE in the morning trade, up 1.32 per cent from the previous close.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
NBSE Announces Class 10 and 12 Examination Results: Females Excel
Japan's Advanced Observation Satellites to Embark on Mission Aboard Third Flight of H3 Rocket
Russia's 'Crab King' given 17-year jail sentence in absentia for ordering murder
CBSE Asked to Plan for Bi-Annual Board Exams, Semester System Not Considered
CBSE to Explore Implementing Twice-Yearly Board Exams from 2025 Without Semester System